Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients.

[1]  P. Gosse,et al.  [Rilmenidine, a new antihypertensive agent in the first line treatment of essential arterial hypertension. Multicenter double-blind study versus atenolol]. , 1991, Presse medicale.

[2]  M. Dontenwill,et al.  Rilmenidine selectivity for imidazoline receptors in human brain. , 1989, European journal of pharmacology.

[3]  M. Dontenwill,et al.  The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. , 1989, European journal of pharmacology.

[4]  R. Podevin,et al.  Interaction of clonidine and rilmenidine with imidazoline‐preferring receptors , 1988, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[5]  P. A. Zwieten.  Pharmacology of the alpha2-adrenoceptor agonist rilmenidine , 1988 .

[6]  F. Lhoste,et al.  Cardiovascular and central nervous system effects of rilmenidine (S 3341) in rats. , 1988, The American journal of cardiology.

[7]  J. Fourtillan,et al.  Pharmacokinetics of rilmenidine in healthy subjects. , 1988, The American journal of cardiology.

[8]  J. Fillastre,et al.  Efficacy and acceptability of rilmenidine for mild to moderate systemic hypertension. , 1988, The American journal of cardiology.

[9]  B. Letac,et al.  A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patients. , 1988, The American journal of cardiology.

[10]  P. Zech,et al.  Pharmacokinetics of rilmenidine. , 1988, The American journal of cardiology.

[11]  S. Laurin,et al.  Efficacy and safety of rilmenidine for arterial hypertension. , 1988, The American journal of cardiology.

[12]  J. Michel,et al.  Antihypertensive efficacy and acceptability of rilmenidine in elderly hypertensive patients. , 1988, The American journal of cardiology.

[13]  C. Dollery,et al.  Dose and concentration-effect relations for rilmenidine. , 1988, The American journal of cardiology.

[14]  J. Reid,et al.  [3H]yohimbine and [3H]idazoxan bind to different sites on rabbit forebrain and kidney membranes. , 1988, European journal of pharmacology.

[15]  J. Fourtillan,et al.  Quantitative analysis of S3341 in human plasma and urine by combined gas chromatography-negative ion chemical ionization mass spectrometry: 15 month inter-day precision and accuracy validation. , 1987, Biomedical & environmental mass spectrometry.

[16]  D. Atlas,et al.  An endogenous, non-catecholamine clonidine antagonist increases mean arterial blood pressure. , 1986, European journal of pharmacology.

[17]  D. Reis,et al.  An endogenous clonidine-like substance binds preferentially to imidazole binding sites in the ventrolateral medulla labelled by 3H-para-aminoclonidine , 1986 .

[18]  Y. Burstein,et al.  Isolation and partial purification of a clonidine-displacing endogenous brain substance. , 1984, European journal of biochemistry.

[19]  J. Schwartz,et al.  Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. , 1984, The Journal of pharmacology and experimental therapeutics.

[20]  D. Perrier,et al.  Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability , 1978, Clinical pharmacology and therapeutics.